Description: <b>5-HTP</b> (5-Hydroxytryptophan) is a naturally occurring amino acid and chemical precursor in the biosynthesis of serotonin(5-HT).<br>
<p><b>5-HTP</b> — 5-Hydroxytryptophan (L-5-HTP) is an endogenous amino-acid intermediate in tryptophan metabolism and the immediate biochemical precursor to serotonin (5-HT) and downstream melatonin. It is most commonly used as an orally administered dietary supplement (often derived from <i>Griffonia simplicifolia</i> seed extracts) rather than as a regulated drug product; common abbreviations include 5-HTP and L-5-HTP. In humans it is rapidly converted by aromatic L-amino-acid decarboxylase (AADC/DDC) to serotonin largely in peripheral tissues unless peripheral decarboxylation is pharmacologically inhibited.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>↑ Serotonin biosynthesis via AADC/DDC conversion of 5-HTP to 5-HT (rate-limited by peripheral decarboxylation and transport into the CNS)</li>
<li>↑ Melatonin biosynthesis (indirect) by increasing serotonin substrate availability in pineal pathways (context-dependent)</li>
<li>↑/↔ Serotonergic GPCR signaling downstream of increased 5-HT tone (5-HT receptor subtype–dependent; includes cAMP/PKA and PLC/IP3/Ca²⁺ axes)</li>
<li>↔ Platelet and vascular serotonergic tone (serotonin uptake/release; hemostasis/vasoreactivity; context-dependent)</li>
<li>Secondary redox modulation via (a) melatonin’s antioxidant signaling and (b) MAO-dependent 5-HT metabolism generating H₂O₂ (context-dependent)</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Oral PK is variable with prominent peripheral conversion to serotonin; historical human PK work reports multi-hour half-life and non-linear/variable exposure, with substantially altered disposition when co-administered with peripheral decarboxylase inhibitors (e.g., carbidopa) which reduces peripheral conversion and can increase CNS availability.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Most mechanistic cellular studies that dose supraphysiologic 5-HTP/5-HT concentrations may exceed achievable free systemic levels with typical supplement dosing; many downstream effects are better interpreted as serotonergic tone (receptor-mediated) rather than direct intracellular target engagement by 5-HTP.</p>
<p><b>Clinical evidence status:</b> Small-human evidence exists primarily in non-oncology indications (e.g., depression) but is limited by study quality/size; there is no credible clinical anticancer evidence base. Safety constraints and interaction risk (serotonergic drugs) are clinically material and often dominate translation decisions.</p>
<p><b>5-HTP (AD context)</b> — In Alzheimer’s disease (AD), 5-HTP is mechanistically relevant only indirectly: it can increase serotonin availability (limited by peripheral decarboxylation) and may secondarily influence sleep/circadian biology via serotonin→melatonin pathways. The human evidence for 5-HTP in AD specifically is not established; available clinical work is better described as small studies in older adults (not necessarily AD) assessing cognition/mood, while broader AD-relevant biology is supported mainly by serotonergic-system and melatonin literature rather than 5-HTP intervention trials.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>↑/↔ Central serotonergic tone (limited/variable CNS delivery; receptor subtype–dependent)</li>
<li>↑ Sleep/circadian support via serotonin→melatonin substrate effects (context-dependent)</li>
<li>↓/↔ Oxidative stress and mitochondrial stress (secondary; largely via melatonin-linked pathways; context-dependent)</li>
<li>↔ Neuroinflammation and synaptic function (secondary; downstream of serotonergic receptor signaling; context-dependent)</li>
</ol>
-Serotonin (from 5-HTP) is further converted into melatonin in the pineal gland, regulating sleep-wake cycles<br>
- 5-HTP freely crosses the blood–brain barrier.<br>
-Serotonin Does not cross the blood-brain barrier well if excessively converted in the periphery, which is why it's often taken with carbidopa (a peripheral decarboxylase inhibitor) in clinical contexts.<br>
-Doses over ~300–400 mg/day should be taken cautiously and under supervision.<br>
-Alzheimer’s Disease (AD) patients show marked reductions in serotonin levels and serotonergic neurons, especially in the raphe nuclei and hippocampus. 5-HTP could help restore serotonin levels in the brain, potentially supporting cognition and mood.<br>
-5-HTP may help reduce microglial activation and inflammatory cytokines (e.g. TNF-α, IL-6), both elevated in AD.<br>
-Serotonin and melatonin (a downstream product of 5-HTP) have antioxidant properties, which might help reduce ROS-induced neuronal damage in AD.<br>
-Many AD patients are on SSRIs or cholinesterase inhibitors, which could interact with 5-HTP.<br>
<br>
<h3>Alzheimer’s-relevant axes for 5-HTP (indirect)</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Modulation</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Central serotonergic function</td>
<td>↑/↔ (delivery-dependent)</td>
<td>P/R</td>
<td>Potential symptom-domain effects (mood, sleep, behavior)</td>
<td>AD biology includes serotonergic-system alterations; 5-HTP’s ability to shift CNS serotonin is variable due to peripheral decarboxylation and competing transport/handling.</td>
</tr>
<tr>
<td>2</td>
<td>Sleep–circadian axis</td>
<td>↑/↔ (context-dependent)</td>
<td>R/G</td>
<td>Sleep consolidation and circadian support</td>
<td>Melatonin disruption is common in AD; 5-HTP may increase serotonin substrate for melatonin synthesis in some contexts, but this is indirect and not reliably demonstrated as an AD intervention.</td>
</tr>
<tr>
<td>3</td>
<td>Mitochondria and oxidative stress</td>
<td>↓/↔ (secondary)</td>
<td>R/G</td>
<td>Redox/mitochondrial stress buffering</td>
<td>Mechanistic support is stronger for melatonin itself in neurodegeneration than for 5-HTP as a means to raise melatonin in AD.</td>
</tr>
<tr>
<td>4</td>
<td>Neuroinflammation and synaptic plasticity</td>
<td>↔ (secondary)</td>
<td>G</td>
<td>Downstream signaling shifts</td>
<td>Serotonergic receptor signaling can modulate inflammatory tone and synaptic function, but directionality is receptor- and circuit-dependent; not a specific 5-HTP signature.</td>
</tr>
<tr>
<td>5</td>
<td>Clinical Translation Constraint</td>
<td>—</td>
<td>—</td>
<td>Evidence gap + interaction + quality control</td>
<td>No AD-specific efficacy base; serotonergic drug interactions matter in older adults; product quality/impurity concerns have been reported historically in some commercial 5-HTP lots.</td>
</tr>
</tbody>
</table>